Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valacyclovir Prophylaxis for CMV Disease in Advanced HIV Infection
NCT00001038Phase 3Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Primary completion
- May 1996
- Modality
- Metabolically Activated Prodrugs
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of valaciclovir in cytomegalovirus infection (CMV) (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Prevention of cytomegalovirus (CMV) end-organ disease and Overall Survival. Status: completed.
02
Drugs
valaciclovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT00001038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001038.